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Leptin is an adipocyte-derived hormone that acts as a major
regulator of food intake and energy homeostasis. It circulates
both as a free and as a protein-bound entity. Leptin is
released into the blood in proportion to the amount of body
fat and exerts sustained inhibitory effects on food intake
while increasing energy expenditure. The leptin receptor
belongs to the class I cytokine receptor superfamily and
possesses strong homology to the signal-transducing
subunits of the IL-6 receptor. The hypothalamic melanocortin
system, and specifically the melanocortin-4 receptor (MC-4R),
is critical in mediating leptin’s effect on appetite and
metabolism. Serum leptin concentrations are elevated in
patients with chronic kidney disease (CKD) and correlate with
C-reactive protein levels suggesting that inflammation is an
important factor that contributes to hyperleptinemia in CKD.
Hyperleptinemia may be important in the pathogenesis of
inflammation-associated cachexia in CKD. We showed that
experimental uremic cachexia was attenuated in db/db mice,
a model of leptin receptor deficiency. Nephrectomy in these
animals did not result in any change in weight gain, body
composition, resting metabolic rate, and efficiency of food
consumption. Furthermore, experimental uremic cachexia
could be ameliorated by blocking leptin signaling through
the hypothalamic MC-4R. MC-4R knockout mice or mice
administered the MC-4R and MC-3R antagonist, agouti-
related peptide, resisted uremia-induced loss of lean
body mass and maintained normal basal metabolic rates.
Thus, melanocortin receptor antagonism may provide a
novel therapeutic strategy for inflammation-associated
cachexia in CKD.
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A decade ago, Friedman and colleagues identified by
positional cloning an obese (OB) gene that is responsible
for obesity in the ob/ob mouse.1 This discovery has initiated
a new era of research on molecular mechanisms of energy
homeostasis. The OB gene encodes a 16-kDa circulating
hormone, named leptin after the Greek word ‘leptos’,
meaning lean. Leptin is an adipocyte-derived hormone that
acts as a major regulator of food intake and energy homeo-
stasis. It circulates both as a free and as a protein-bound
entity. Structural studies demonstrate leptin as a member
of the growth hormone four-helical cytokine subfamily.
Comparative structural analysis results in a phylogeny
that positions leptin in a subfamily that includes growth
hormone, erythropoietin, leukemia inhibitory factor, and
interleukins (IL) 2, 3, 4, 5, 6, and 10. Specifically, within this
structural family, leptin resides in the middle of the long- and
short-chain helical members, closest to IL-6.2
LEPTIN RECEPTORS
Tartaglia et al.3 identified the leptin receptor gene in the db
locus of the mouse chromosome 4. The leptin receptor
belongs to the class I cytokine receptor superfamily. The
extracellular leptin-binding domain of the leptin receptor
possesses strong homology to the gp130 signal-transducing
subunits of receptor for IL-6 and leukemia inhibitory factor.
All of these receptors, including the leptin receptor, couple to
the Janus kinase/signal transducer and activator of transcrip-
tion signal transduction pathway. At least five isoforms
(OBRa, OBRb, OBRc, OBRd, and OBRe) are known to exist
and result from alternate gene splicing.4 All leptin receptors
share an identical N-terminal ligand-binding domain but
differ at the C-terminal region. The OBRa, OBRb, OBRc, and
OBRd receptor isoforms contain a single transmembrane
region, whereas the OBRe receptor is truncated proximal to
the membrane-spanning domain. This last receptor isoform
without a membrane anchor functions as a circulating
soluble leptin-binding receptor (SLR) protein.5 OBRb is
primarily expressed in the hypothalamus, where its action is
important in the regulation of energy homeostasis. OBRb
expression is also detected in a large number of peripheral
tissues including skeletal muscle, heart, adrenals, kidneys,
adipocytes, immune cells, liver, and pancreatic cells. Thus,
leptin may have a wide spectrum of peripheral functions as
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well.6 The functions of other isoforms of the leptin receptor
with shortened cytoplasmic domains (OBRa, OBRc, OBRd)
have yet to be determined. These receptors are abundantly
expressed in most tissues and have been suggested to
function in leptin clearance or to facilitate transport into
the central compartment.7,8
LEPTIN TRANSPORT AND SENSITIVITY
There is evidence to suggest that central leptin sensitivity may
be related to its transport across the blood–brain barrier. In
obese humans, who are leptin resistant, the ratio of leptin in
cerebrospinal fluid to plasma is decreased, indicating that the
capacity for leptin transport into the brain is reduced. This
apparent reduction in leptin transport into the central
nervous system may be a significant cause of leptin resistance
in obesity.9 Rodents with obesity from overfeeding do not
lose weight when leptin is administered peripherally but
respond robustly to leptin when it is given intracerbroven-
trically.10 Leptin is transported across the blood–brain barrier
in mice in which a nonsense mutation in the extracellular
domain of the leptin receptor deletes all functional receptor
isoforms.11 However, the exact nature of the putative
leptin transporter and its physiological regulation remain to
be determined.
LEPTIN ACTION ON APPETITE AND ENERGY HOMEOSTASIS
Leptin is released into the blood in proportion to the amount
of body fat and exerts sustained inhibitory effects on food
intake while increasing energy expenditure. When body fat
stores fall, declining levels of leptin are sensed by the brain
and are transduced into increases in appetite and metabolic
efficiency that persist until the lost weight is recovered. In
addition, short-duration, meal-related ‘satiety’ signals, such
as cholecystokinin and peptide YY, are released from the
gastrointestinal tract during eating. These peptides promote a
sense of ‘fullness’ that encourages an end to the meal. Ghrelin
is another gut peptide that increases with fasting and is
thought to trigger the onset of eating by stimulating appetite.
Collectively, these hormones participate in a meal-to-meal
control system that is itself sensitive to changes in insulin
and leptin levels. In this way, the size and frequency of
individual meals can be adjusted so as to minimize changes
in body fat content.12
The melanocortin system is critical in mediating leptin’s
effect on metabolism and that there are distinct local
counterparts of the pro-opiomelanocortin (POMC) cells:
agouti-related protein (AgRP) and neuropeptide Y (NPY)
producing cells in the arcuate nucleus. Activation of POMC
neurons by leptin triggers the release of a-melanocyte-
stimulating hormone from POMC axon terminals, which in
turn activates the type 4 melanocortin receptor (MC-4R),
leading to suppressed food intake and increased energy
expenditure. Simultaneously, leptin suppresses the activity of
arcuate nucleus NPY/AgRP neurons, which otherwise would
antagonize the effect of a-melanocyte-stimulating hormone
(a-MSH) on MC-4Rs through the release of AgRP. Not only
does the NPY/AgRP system antagonize anorexigenic mela-
nocortin cells at their target sites, where MC-4Rs are located,
but it also very robustly and directly inhibits POMC
perikarya through both NPY and the inhibitory neurotrans-
mitter GABA, which acts through basket-like synaptic
innervation of POMC cells by NPY/AgRP cell terminals.
This apparent unidirectional anatomical interaction
between the NPY/AgRP and POMC perikarya is of
potential significance, as it provides a tonic inhibition of
the melanocortin cells whenever the NPY/AgRP neurons
are active.13,14
Both NPY/AgRP and POMC neuronal systems are
directly targeted by leptin and can also be affected by other
peripheral metabolic signals, such as ghrelin, glucose,
insulin and peptide YY, a putative satiety signal released
from the gastrointestinal tract postprandially in proportion
to the calorie content of a meal.15 Their localization in
ventromedial aspects of the arcuate nucleus close to the
median eminence, a region with an attenuated blood–brain
barrier between vessels and the parenchyma, means that these
neurons might be reached by circulating metabolic signals in
the most effective manner. Indeed, NPY/AgRP or POMC
perikarya or dendrites are often seen in direct contact with
capillaries, thus increasing the likelihood that these neurons
are direct targets of peripheral signals.13,14
LEPTIN ACTION AS AN INFLAMMATORY CYTOKINE
Shamsuzzaman et al.16 demonstrated an association between
serum levels of leptin and C-reactive protein (CRP) in
healthy young adults. The investigators postulate that leptin
correlates with CRP either because leptin directly stimulates
the production of IL-6 or because obese patients tend to
produce large quantities of leptin and IL-6. Ble et al.17 used
data from a large population-based epidemiology study of
older subjects to show that serum levels are directly
associated with CRP and that this association is independent
of IL-6, other cytokines, and a number of potentially
confounders such as adiposity, lifestyle, drugs, and diseases.
Treatment of overweight men with a leptin analogue during a
low-calorie diet prevented the CRP decrease usually observed
during weight loss, without affecting IL-6 levels.18 Leptin
directly stimulates the production of acute-phase proteins
such as CRP in liver cells.19 Both leptin and IL-6 receptors are
expressed on hepatocyte cell surface.3,20 Leptin receptors can
activate intracellular Janus kinase/signal transducer and
activator of transcription signaling pathways normally
activated by IL-6.20 It is possible that these shared pathways
explain the similarity of effects between leptin and IL-6 on
CRP production. As a cytokine, leptin appears to serve in
thymic homeostasis and to contribute to the regulation of
immune function.6
LEPTIN IN CHRONIC KIDNEY DISEASE
Serum leptin concentrations are elevated in chronic kidney
disease (CKD). The mechanism underlying elevated serum
leptin levels in patients with CKD differs from that in obese
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patients. Leptin is cleared from the circulation by the kidney
by glomerular filtration followed by metabolic degradation in
the renal tubules.21 In patients with normal renal function,
there is a net renal intake of 12% of circulating leptin,
whereas in patients with CKD, there is no renal update of
leptin.22 In hemodialysis patients, serum leptin levels factored
for body mass index was increased by fourfold compared
with healthy controls. Serum leptin is not effectively cleared
by hemodialysis with cellulose membranes.22 Furthermore,
leptin release from adipose tissue is decreased by metabolic
acidosis.23 Thus, the presence of metabolic acidosis in end-
stage renal disease patients may partially mask their
hyperleptinemia. In a cross-sectional study of 219 patients
with various degrees of CKDs, significant correlations were
found between leptin levels and glomerular filtration rate and
body mass index. Leptin gene expression in adipose tissue
from CKD patients was decreased. Thus, decreased plasma
leptin clearance in CKD may be part of an efferent feedback
loop that downregulates the expression of the OB gene in
hyperleptinemic patients with advanced CKD. Furthermore,
a significant correlation between leptin and CRP concentra-
tions were also demonstrated in CKD patients, suggesting
that inflammation is an important factor that contributes to
hyperleptinemia in CKD.24 Longitudinal studies showed that
peritoneal dialysis (PD) patients who were cachexia, with
loss of lean body mass during the observation period, had
higher initial CRP levels. A significant increase in serum
leptin concentrations was observed in PD patients who
lost lean body mass, whereas no such change was observed
in PD patients who gained lean body mass. This suggests
that hyperleptinemia may be an important cause of uremic
cachexia.25
Pecoits-Filho et al.26 studied 149 non-obese end-stage
renal disease patients in order to analyze the association
between serum leptin, SLR, inflammation, and body
composition. These investigators found significantly elevated
serum leptin concentrations but normal SLR concentrations
in the end-stage renal disease patients compared with healthy
controls with normal renal function. A negative correlation
was observed between serum leptin and SLR in the end-stage
renal disease patients. A positive correlation was observed
between lean body mass and the SLR/serum leptin ratio. Fat
mass was negatively correlated with both SLR and SLR/serum
leptin ratio. Furthermore, a positive correlation was found
between IL-6 and serum leptin concentrations. These results
suggest that free circulating bioactive leptin concentrations
are elevated in patients with end-stage renal disease and may
be associated with inflammatory-associated cachexia.26
Voegeling and Fantuzzi27 showed that inflammation induced
by lipopolysaccharide injections is associated with a very
significant increase in serum leptin and only a marginal
increase in SLR concentrations, again suggesting that free
circulating bioactive leptin concentrations are present in this
model of infection-associated cachexia. Furthermore, Huang
et al.28 demonstrated that lipopolysaccharide-induced anor-
exia in rats can be reversed by a central melanorcortin
antagonist. Indeed, Marks et al.29 have shown more recently
that cachexia induced by lipopolysaccharide and tumor
growth can be ameliorated by blocking leptin signaling
through the hypothalamic MC-4R. MC-4R knockout (KO)
mice or mice administered the MC-4R and MC-3R
antagonist, AgRP, resist tumor-induced loss of lean body
mass and maintain normal basal metabolic rates during
tumor growth29 (Figure 1).
LEPTIN AND MELANOCORTIN SIGNALING IN UREMIC
CACHEXIA
We tested the hypothesis that leptin was an important cause
of uremic cachexia via signaling through its receptor.30 Our
results showed that uremic cachexia was attenuated in db/db
mice, a model of leptin receptor deficiency. Nephrectomy in
these animals did not result in any change in weight gain,
body composition, resting metabolic rate, and efficiency of
food consumption. Recent studies suggested that db/db mice
resisted lipopolysaccharide-induced anorexia by reducing
tumor necrosis factor-a secretion.31 Thus, leptin may have an
important role in the regulation of appetite, body composi-
tion, and metabolic rate in uremia. Indeed, elevated serum
leptin was associated with lower dietary intake and higher
catabolic rate in uremic children.32
We demonstrated that uremic cachexia in experimental
animals can be attenuated by blocking leptin signaling
through the central MC-4R. Both homozygous and hetero-
zygous MC-4RKO mice had no decrease in appetite after
nephrectomy compared with wild-type sham animals. The
most striking difference was that both the homozygous and
heterozygous MC-4RKO animals continued to gain lean body
mass and fat mass with no change in the food consumption
efficiency despite the cachexic effects of uremia as demon-
strated in the wide-type nephrectomized controls. The effects
of nephrectomy on increasing resting metabolic rate as
demonstrated in the wild-type animals were also much
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Figure 1 | Experimental strategies for treatment of uremic
cachexia (Cheung et al.30). (1) Leptin receptor (OBRb) knockout.
(2) MC-4R knockout. (3) AgRP, antagonist for MC-4R and MC-3R.
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attenuated in both the homozygous group and the hetero-
zygous group. These results are consistent with previous
observations that MC-4RKO animals maintained normal
metabolic rate and body composition, even when bearing a
carcinoma that produced classic cachexia in wild-type
control animals.29 These data strongly suggest that the
hypothalamic MC-4R plays a significant role in transducing
cachexigenic signals in uremia.
We further tested the effect of central melanocortin
receptor antagonism in the experimental uremic cachexia
models using a pharmacological approach. These data clearly
demonstrated that uremic cachexia is ameliorated by central
administration of AgRP in wild-type nephrectomized mice.
Repeated intracranial infusion of AgRP significantly increased
food intake, weight gain including both lean and fat mass, as
well as efficiency of food consumption. At the same time,
resting metabolic rate was decreased by AgRP. Circulating
leptin concentrations were elevated in wild-type nephrecto-
mized mice but normalized in AgRP-treated wild-type
nephrectomized mice. These data are consistent with the role
of AgRP as an antagonist for MC-4R and with previous
studies demonstrating that tumor-induced and sepsis-induced
cachexia is attenuated by MC-4R blockade with AgRP.30
CONCLUSION
Leptin signaling, through the hypothalamic melanocrotin
receptors, may play an important role in the pathogenesis of
inflammation-associated cachexia in CKD. Elucidation of the
mechanisms regulating appetite and metabolic rate will
permit new insights into the pathophysiology of uremic
cachexia. We recently showed that experimental uremic
cachexia was attenuated in db/db mice, a model of leptin
receptor deficiency. Nephrectomy in these animals did not
result in any change in weight gain, body composition,
resting metabolic rate, and efficiency of food consumption.
Furthermore, MC-4RKO mice or mice administered the
MC-4R and MC-3R antagonist, AgRP, resisted uremia-
induced loss of lean body mass and maintained normal
basal metabolic rates. These recent findings increase our
understanding of the pathogenesis and may provide the basis
of a novel therapeutic strategy for inflammation-associated
cachexia in CKD.
ACKNOWLEDGMENTS
This work was supported by grants from the National Institute of
Health, R01 DK 50780 and K24 DK59574 to RHM and K08 DK 62207
to DLM.
REFERENCES
1. Zhang Y, Procena R, Maffei M et al. Positional cloning of the mouse obese
gene and its human homologues. Nature 1994; 372: 425–432.
2. Gaucher EA, Miyamoto MM, Benner SA. Evolutionary, structural and
biochemical evidence for a new interaction site of the leptin obesity
protein. Genetics 2003; 163: 1549–1553.
3. Targlia LA, Dembski M, Weng X et al. Identification and expression
cloning of a leptin receptor OB-R. Cell 1995; 83: 1263–1271.
4. Lee GH, Proenca R, Montez JM et al. Abnormal splicing of the leptin
receptor in diabetic mice. Nature 1996; 379: 632–635.
5. Lammert A, Kiess W, Bottner A et al. Soluble leptin receptor represents
the main leptin binding activity in human blood. Biochem Biophy Res
Commun 2001; 283: 982–988.
6. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and
biology. Vitam Horm 2005; 71: 345–372.
7. Banks WA, Kastin AJ, Huang W et al. Leptin enters the brain by a saturable
system independent of insulin. Peptides 1996; 17: 305–311.
8. Hileman SM, Tornoe J, Flier JS et al. Transcellular transport of leptin by the
short leptin isoform ObRa in Madin–Darby Canine kidney cells.
Distribution of leptin receptor rRNA isoforms in the rat brain.
Endocrinology 2000; 141: 1955–1961.
9. Bryson JM. The future of leptin and leptin analogues in the treatment of
obesity. Diabetes Obes Metabol 2000; 2: 83–89.
10. Halaas JL, Boozer C, Blair-West J et al. Physiological response to long-term
peripheral and central leptin infusion in lean and obese mice. Proc Natl
Acad Sci USA 1997; 94: 8878–8883.
11. Takaya K, Ogawa Y, Hiradoka J et al. Nonsense mutation of leptin
receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet
1996; 14: 130–131.
12. Schwartz MW, Morton GJ. Keeping hunger at bay. Nature 2002; 418:
595–597.
13. Horvath TL. The hardship of obesity: a soft-wired hypothalamus. Nature
Neurosci 2005; 8: 561–565.
14. Cone RD. Anatomy and regulation of the central melanocortin system.
Nature Neurosci 2005; 8: 571–578.
15. Cowley MA, Smart JL, Rubinstein M et al. Leptin activates anorexigenic
POMC neurons through a neural network in the arcuate nucleus. Nature
2001; 411: 480–484.
16. Shamsuzzaman AS, Winnicki M, Wolk R et al. Independent association
between plasma leptin and CRP in healthy humans. Circulation 2004; 109:
2181–2185.
17. Ble A, Windham G, Bandinelli S et al. Relation of plasma leptin to
C-reactive protein in older adults. Am J Cardiol 2005; 96: 991–995.
18. Hukshorn CJ, Lindeman JH, Toet KH et al. Leptin and the proinflammatory
state associated with human obesity. J Clin Endocrinol Metab 2004; 89:
1773–1778.
19. Dowidar NL, Dejong CHC, Fearson KCH et al. Effects of leptin on isolated
human hepatocyte C reactive protein production. Eur J Gastroenterol
Hepatol 2000; 12: A18.
20. Wang Y, Kuropetwinski KK, White DW et al. Leptin receptor action in
hepatic cells. J Biol Chem 1997; 272: 16216–16223.
21. Cumin F, Baum HP, De Gasparo M, Levens N. Leptin is cleared from the
circulation primarily by the kidney. Int J obes Relat Metab Disord 1997; 21:
495–504.
22. Sharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by
the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51:
1980–1985.
23. Teta D, Bevington A, Brown J et al. Effect of acidosis on leptin secretion
from 3T3 adipocytes and on serum leptin in the uraemic rat. Clin Sci 1999;
97: 363–368.
24. Nordfors L, Lonnqvist F, Heimburger O et al. Low leptin gene expression
and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54:
1267–1275.
25. Stenvinkel P, Lindholm B, Lonnqvist F et al. Increases in serum leptin
levels during peritoneal dialysis are associated with inflammation and a
decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303–1309.
26. Pecoits-Filho R, Nordfors L, Heimburger O et al. Soluble leptin receptors
and serum leptin in end-stage renal disease: relationship with
inflammation and body composition. Eur J Clin Invest 2002; 32: 811–817.
27. Voegeling S, Fantuzzi G. Regulation of free and bound leptin and
soluble leptin receptors during inflammation in mice. Cytokine 2001;
14: 97–103.
28. Huang QH, Hruby VJ, Tatro JB. Role of central melanocortins in
endotoxin-induced anorexia. Am J Physiol 1999; 276: R864–R871.
29. Marks DL, Ling N, Cone RD. Role of central melanocortin system in
cachexia. Cancer Res 2001; 61: 1432–1438.
30. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin
signaling in uremia-associated cachexia. J Clin Invest 2005; 115:
1659–1665.
31. Madiehe AM, Mitchell TD, Harris RB. Hyperleptinemia and reduced
TNF-alpha secretion cause resistance of db/db mice to endotoxin.
Am J Physiol Regul Integr Comp Physiol 2003; 284: R763–R770.
32. Daschner M, Tonshoff B, Blum WF et al. Inappropriate elevate of serum
leptin in children with chronic renal failure. European Study Group for
Nutritional Treatment of Chronic Renal Failure in Childhood. J Am Soc
Nephrol 1998; 9: 1074–1079.
Kidney International (2006) 69, 794–797 797
RH Mak et al.: Leptin and inflammation-associated cachexia m i n i r e v i e w
